RxDoctor Payments DataLook up a doctor →

Laura Herpel, MD

Pulmonary Disease · Columbia, SCNPI 1558411751

Payments from drug & device makers

$441,642in general payments, 2019–2025

Across 602 payments — averaging $733.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$156K
  • Jazz Pharmaceuticals Inc.$101K
  • Avadel CNS Pharmaceuticals, LLC$81K
  • Harmony Biosciences LLC$23K
  • Idorsia Pharmaceuticals US Inc$22K
  • GSK$17K
  • plus $42K from 23 others
$1,569in research payments, 2019–2025

Across 9 payments — averaging $174.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$2K

What the payments were for

  • Consulting fees$102,09540%
  • Speaking & faculty fees$104,93941%
  • Travel & lodging$31,38912%
  • Food & beverage$15,3806%
  • Education$4560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$441,642 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$147,416
Medicare patients
526
Services billed
1,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon11$393,957
WakixPitolisant Hcl14$222,573
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$125,349
XywavSodium,calcium,mag,pot Oxybate14$88,915
BelsomraSuvorexant99$49,698
SunosiSolriamfetol Hcl49$38,250
Breo ElliptaFluticasone/Vilanterol40$22,416
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,285
DayvigoLemborexant39$12,608
QuviviqDaridorexant Hcl20$10,509
Spiriva RespimatTiotropium Bromide16$10,308
Doxepin Hcl103$9,127
SymbicortBudesonide/Formoterol Fumarate20$6,802
Armodafinil80$4,626
Albuterol Sulfate HfaAlbuterol Sulfate123$4,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Hetlioz$146$393,95711 claims
Harmony Biosciences LLCWakix$22,769$222,57314 claims
GSKTrelegy Ellipta, Breo Ellipta$16,738$147,765185 claims
MerckBelsomra$227$49,69899 claims
Axsome Therapeutics, Inc.Sunosi$6,543$38,25049 claims
AstraZenecaBreztri Aerosphere, Symbicort$9,402$21,08735 claims
Eisai Inc.Dayvigo$133$12,60839 claims
Idorsia Pharmaceuticals US IncQuviviq$22,251$10,50920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →